BioVie Reports Symptom Improvement Trend in Phase 2 Long COVID Trial
BioVie said its Bezisterim trial showed a trend toward symptom improvement. The supplied report is truncated and provides no further trial details.
BioVie said its Bezisterim trial showed a trend toward symptom improvement. The supplied report is truncated and provides no further trial details.